No local or systemic adverse effects were seen from either treatment group.

Statistical analysis: Data were analyzed as mean values for each treatment group.

Regression rates were similar by treatment group in patients with low VEGF.

This is explained by a higher restenosis rate in this treatment group.

Two patients died during the study period, 1 in each treatment group.

At baseline, there were no significant treatment group differences in OT levels.

The control pups of the first treatment group were untreated litter mates.

The incidence of reperfusion-induced arrhythmias was significantly lower in the treatment group.

All participants, investigators, and the sponsor were masked to treatment group assignment.

Results: A total of 473 employees in each treatment group were identified.

Results: No significant safety issues were observed in any treatment group.

Parents also reported improved sports skills and good sportsmanship in the treatment group.

Symptomatic improvement was seen in at least 10 patients in each treatment group.

During the first month of treatment , ALT levels declined gradually in treatment group.

There were few severe adverse events or laboratory abnormalities in either treatment group.

Responsiveness to change was calculated for all patients and in each treatment group.